R&D Partner Content 6th Treg Directed Therapies Summit Get ready for the much-anticipated return of the 6th Treg-Directed Therapies Summit! This year promises an enhanced experience wi
Views & Analysis Gene editing: beyond the hype Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.